PROACT - Pre-Operative Arimidex Compared To Tamoxifen

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 30, 2005
Last updated: February 2, 2010
Last verified: February 2010
The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated. The main objectives of this research study are to see whether using these drugs will shrink down tumours before surgery and to see if any shrinkage in the tumour affects the extent of surgery that is required.

Condition Intervention Phase
Breast Cancer
Drug: ARIMIDEX (anastrazole)
Drug: NOLVADEX (tamoxifen)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Objective tumour response [ Time Frame: Assessed at 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pathological response [ Time Frame: Assessed at 3 months ] [ Designated as safety issue: No ]
  • Extent of breast surgery [ Time Frame: Assessed at 3 months ] [ Designated as safety issue: No ]
  • Extent of axillary down-staging [ Time Frame: Assessed at 3 months ] [ Designated as safety issue: No ]
  • Clinical ultrasound response versus clinical caliper response [ Time Frame: Assessed at 3 months ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: Assessed up to 5 years + 30 days ] [ Designated as safety issue: No ]
  • Complications due to surgery [ Time Frame: Assessed up to 30 days post-surgery ] [ Designated as safety issue: No ]
  • Health economics outcomes [ Time Frame: Assessed up to 30 days post-surgery ] [ Designated as safety issue: No ]
  • Quality of Life assessments [ Time Frame: Assessed at 3 months ] [ Designated as safety issue: No ]
  • Effect of ethnicity with respect to baseline patient and tumour characteristics, safety and objective tumour response rate [ Time Frame: Assessed up to 5 years + 30 days ] [ Designated as safety issue: No ]
  • Recurrence-free survival and survival [ Time Frame: Assessed up to 5 years ] [ Designated as safety issue: No ]

Enrollment: 452
Study Start Date: August 2000
Study Completion Date: December 2007
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Operable or potentially operable breast cancer
  • Invasive breast cancer proven to be hormone-sensitive (ER+/PR+)
  • Patients who might benefit from endocrine treatment prior to surgery
  • Postmenopausal
  • Signed written informed consent

Exclusion Criteria:

  • Inoperable breast cancer
  • Patient unwilling to undergo surgery
  • Any reason why the patient may not be able to conform to study requirements
  • Any previous treatment for breast cancer
  • Previous Tamoxifen use as a part of breast cancer prevention trials
  • Not willing to stop taking drugs that affect sex-hormones such as HRT
  • Previous history of breast cancer
  • Previous history of invasive malignancy within the last 10 years
  • Any other severe disease that may prevent surgery, place the patient at risk, or influence the study results
  • Treatment with an experimental drug within the last 3 months
  • Risk of transmitting HIV, Hepatitis B or C
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00232661

  Show 79 Study Locations
Sponsors and Collaborators
Study Director: AstraZeneca Arimidex Medical Science Director, MD AstraZeneca
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Francisco Sapunar, MD - Arimidex Medical Science Director, AstraZeneca Identifier: NCT00232661     History of Changes
Other Study ID Numbers: 1033IL/0039  D5395C00039 
Study First Received: September 30, 2005
Last Updated: February 2, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Bone Density Conservation Agents
Enzyme Inhibitors
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Therapeutic Uses processed this record on February 10, 2016